IP Library Granted Patent US 11,576,975
Granted Patent B2
US 11,576,975 · App. 17/027,318 · Granted Feb 14, 2023

Compositions and methods for delivering an agent to a wound

Inventors: Warren O. Haggard (Memphis, TN); Scott P. Noel (Memphis, TN); Joel D. Bumgardner (Memphis, TN)
Assignee: UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION
A61K47/36A61K9/7007A61K31/00A61K31/7036A61K38/14A61L15/28A61L15/44A61L27/20A61L27/58A61L29/043A61L29/146A61L29/148A61L29/16A61L31/042A61L31/146A61L31/148A61L31/16C08B37/003C08J5/18C08L5/08A61K9/0024A61L2300/232A61L2300/25A61L2300/406C08J2305/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,576,975
App. No.
17/027,318
Granted
Feb 14, 2023
Kind
B2
Abstract

The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).

Claims (10)

1. A chitosan sponge comprising a hemostatic agent produced by, a method comprising:

(a) dissolving chitosan in one or more acids in a solvent, wherein the acid and solvent are selected to produce a chitosan that biodegrades over at least about one, two, three, four or five days in vivo;

(b) forming the chitosan into a desired shape and lyophilizing to reduce the water content by about 10%-100%;

(c) neutralizing the chitosan composition by contacting the composition with a basic solution, wherein the basic solution is selected to modulate a physical-mechanical property of the chitosan;

(d) lyophilizing the composition of step (c) to reduce the water content by about 80%-100%; and

(e) incorporating an effective amount of the hemostatic agent into the composition, thereby producing a biodegradable chitosan sponge.

2. A wound management device comprising the chitosan sponge of claim 1 .

3. The wound management device of claim 2 , wherein the device degrades within 1-35 days.

4. A medical device for implantation comprising the chitosan sponge of claim 1 .

5. A kit comprising the chitosan sponge of claim 1 , the wound management device of claim 2 , or the medical device of claim 4 for use in treating a trauma site or delivering an hemostatic agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2020
From: HAGGARD, WARREN O.; NOEL, SCOTT P.; BUMGARDNER, JOEL D.
To: UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION
Reel/Frame 053843/0092 →